News

Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation
LIVMARLI Tablet formulation approved for patients with Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic ...
Business Wire4d
Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation
--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of LIVMARLI ...
Seeking Alpha3d
Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation
--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of LIVMARLI ® (maralixibat) for the ...
MPR3d
New Tablet Formulation of Livmarli Gets FDA Approval
The Food and Drug Administration (FDA) has approved a tablet formulation of Livmarli ® (maralixibat).
Mirum Pharmaceuticals receives FDA approval for Livmarli tablet formulation
Mirum announced the FDA approved a new tablet formulation of Livmarli for the treatment of cholestatic pruritus in patients with Alagille ...
Morningstar22d
LIVMARLI Now Approved in Japan for ALGS and PFIC
LIVMARLI is the first and only treatment available for cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestasis in Japan Mirum Pharmaceuticals ...
Nasdaq27d
Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe
Mirum Pharmaceuticals’ MIRM lead product, Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) inhibitor, is approved for the treatment of cholestatic pruritus ...